FIELD: biotechnology.
SUBSTANCE: described is a recombinant adeno-associated expression vector (rAAV) comprising a genetic construct which contains a promoter operably linked to a first coding sequence, which codes a receptor tyrosine kinase B (TrkB), and a second coding sequence which codes a TrkB receptor agonist, wherein the agonist is a mature NFGM or mature NT-4, wherein the second coding sequence comprises a nucleotide sequence encoding a signal peptide for a TrkB receptor agonist, such that when the signal peptide is conjugated to the N-terminus of the mature HPGM, and wherein the genetic construct comprises a spacer sequence located between the first and second coding sequences, wherein said spacer sequence encodes a peptide spacer, which is configured for splitting to thereby produce a TrkB receptor and agonist in the form of separate molecules.
EFFECT: invention can be used for treating, preventing or alleviating a pathology of the optic nerve or cochlear pathology or for stimulating regeneration and/or survival of nerves.
41 cl, 1 ex, 17 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NON-HUMAN ANIMALS CONTAINING THE HUMANIZED TrkB LOCUS | 2018 |
|
RU2800428C2 |
| GENETIC STRUCTURE FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE | 2018 |
|
RU2757932C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| PREPARATION CONTAINING VIII FACTOR AND VON WILLEBRAND FACTOR PEPTIDES | 2015 |
|
RU2714154C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
| SOLUBILIZED APIRASES, METHODS AND APPLICATIONS | 2019 |
|
RU2791992C2 |
| ISOLATION OF A NEW PESTIVIRUS CAUSING CONGENITAL TREMOR A | 2017 |
|
RU2765658C2 |
